Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
To assess whether albumin administration after an episode of hepatic encephalopathy (≥ grade
II) improves survival at 90 days (mortality endpoint treated as a composite endpoint death
and/ or liver transplantation).
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute